Participant flow

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017) · Source last updated 2020-02-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received a single 0.5-mL intramuscular injection of the 9-valent human papillomavirus (9vHPV) vaccine at Day 1, Month 2, and Month 6

   id

   FG000

   title

   9vHPV Vaccine

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Protocol Violation

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         201

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         200

      type

      Vaccination 1

   3. achievements

      1. group Id

         FG000

         num Subjects

         200

      type

      Vaccination 2

   4. achievements

      1. group Id

         FG000

         num Subjects

         198

      type

      Vaccination 3

   5. achievements

      1. group Id

         FG000

         num Subjects

         198

      type

      COMPLETED

   6. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice